Autor segons l'article: Gabaldon-Figueira, Juan Carlos; Ros-Lucas, Albert; Martinez-Peinado, Nieves; Blackburn, Gavin; Losada-Galvan, Irene; Posada, Elizabeth; Ballart, Cristina; Escabia, Elisa; Capellades, Jordi; Yanes, Oscar; Pinazo, Maria-Jesus; Gascon, Joaquim; Alonso-Padilla, Julio
Departament: Enginyeria Electrònica, Elèctrica i Automàtica
Autor/s de la URV: Yanes Torrado, Óscar
Paraules clau: <italic>trypanosoma cruzi</italic>; Adult; Biomarkers; Chagas disease; Chromatography, liquid; Chronic disease; Disease progression; Female; Humans; Hydroxydecanoic acid; Lipidomics; Lipids; Male; Mass spectrometry; Metabolis; Metabolomics; Middle aged; Phosphatidylethanolamine; Sphingolipid; Sphingolipids; Treatment outcome; Treatment response; Trypanosoma cruzi
Resum: BackgroundChagas disease, caused by the parasite Trypanosoma cruzi, is a zoonosis that affects more than seven million people. Current limitations on the diagnosis of the disease hinder the prognosis of patients and the evaluation of treatment efficacy, slowing the development of new therapeutic options. The infection is known to disrupt several host metabolic pathways, providing an opportunity for the identification of biomarkers.MethodsThe metabolomic and lipidomic profiles of a cohort of symptomatic and asymptomatic patients with T. cruzi infection and a group of uninfected controls were analysed using liquid chromatography/mass spectrometry. Differences among all groups and changes before and after receiving anti-parasitic treatment across those with T. cruzi infection were explored.ResultsThree lipids were found to differentiate between symptomatic and asymptomatic participants: 10-hydroxydecanoic acid and phosphatidylethanolamines PE(18:0/20:4) and PE(18:1/20:4). Additionally, sphinganine, 4-hydroxysphinganine, hexadecasphinganine, and other sphingolipids showed post-treatment abundance similar to that in non-infected controls.ConclusionsThese molecules hold promise as potentially useful biomarkers for monitoring disease progression and treatment response in patients with chronic T. cruzi infection.
Àrees temàtiques: Biodiversidade; Biotecnología; Ciência da computação; Ciências agrárias i; Ciências ambientais; Ciências biológicas i; Ciências biológicas ii; Ciências biológicas iii; Enfermagem; Engenharias i; Engenharias ii; Engenharias iii; Ensino; Farmacia; Geografía; Infectious diseases; Interdisciplinar; Materiais; Medicina i; Medicina ii; Medicina veterinaria; Parasitology; Química; Saúde coletiva; Tropical medicine; Veterinary (all); Zootecnia / recursos pesqueiros
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: oscar.yanes@urv.cat
Data d'alta del registre: 2024-11-23
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-024-06548-3
Referència a l'article segons font original: Parasites & Vectors. 17 (1): 459-
Referència de l'ítem segons les normes APA: Gabaldon-Figueira, Juan Carlos; Ros-Lucas, Albert; Martinez-Peinado, Nieves; Blackburn, Gavin; Losada-Galvan, Irene; Posada, Elizabeth; Ballart, Crist (2024). Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection. Parasites & Vectors, 17(1), 459-. DOI: 10.1186/s13071-024-06548-3
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI de l'article: 10.1186/s13071-024-06548-3
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2024
Tipus de publicació: Journal Publications
Repositori URV